These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24395136)

  • 1. Striatal volume deficits in children with ADHD who present a poor response to methylphenidate.
    Moreno A; Duñó L; Hoekzema E; Picado M; Martín LM; Fauquet J; Vives-Gilabert Y; Bulbena A; Vilarroya O
    Eur Child Adolesc Psychiatry; 2014 Sep; 23(9):805-12. PubMed ID: 24395136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.
    Rubia K; Halari R; Cubillo A; Mohammad AM; Brammer M; Taylor E
    Neuropharmacology; 2009 Dec; 57(7-8):640-52. PubMed ID: 19715709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional dysconnectivity of corticostriatal circuitry and differential response to methylphenidate in youth with attention-deficit/hyperactivity disorder.
    Hong SB; Harrison BJ; Fornito A; Sohn CH; Song IC; Kim JW
    J Psychiatry Neurosci; 2015 Jan; 40(1):46-57. PubMed ID: 25266402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
    Efron D; Jarman F; Barker M
    Pediatrics; 1997 Dec; 100(6):E6. PubMed ID: 9382907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic imaging study with [Tc-
    Akay AP; Kaya GÇ; Kose S; Yazıcıoğlu ÇE; Erkuran HÖ; Güney SA; Oğuz K; Keskin D; Baykara B; Emiroğlu Nİ; Eren MŞ; Kızıldağ S; Ertay T; Özsoylu D; Miral S; Durak H; Gönül AS; Rohde LA
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():294-300. PubMed ID: 29684537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
    Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
    Quinn D
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.
    Angyal N; Horvath EZ; Tarnok Z; Richman MJ; Bognar E; Lakatos K; Sasvari-Szekely M; Nemoda Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):122-128. PubMed ID: 29374517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.
    Bellgrove MA; Hawi Z; Kirley A; Fitzgerald M; Gill M; Robertson IH
    Neuropsychopharmacology; 2005 Dec; 30(12):2290-7. PubMed ID: 16123773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence.
    Crunelle CL; van den Brink W; Veltman DJ; van Emmerik-van Oortmerssen K; Dom G; Schoevers RA; Booij J
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1714-23. PubMed ID: 23731497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between regional cerebral blood flow and response to methylphenidate in children with attention-deficit hyperactivity disorder: comparison between non-responders to methylphenidate and responders.
    Cho SC; Hwang JW; Kim BN; Lee HY; Kim HW; Lee JS; Shin MS; Lee DS
    J Psychiatr Res; 2007 Sep; 41(6):459-65. PubMed ID: 16839567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grey matter volumes in treatment naïve vs. chronically treated children with attention deficit/hyperactivity disorder: a combined approach.
    Villemonteix T; De Brito SA; Kavec M; Balériaux D; Metens T; Slama H; Baijot S; Mary A; Peigneux P; Massat I
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1118-27. PubMed ID: 25934396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
    Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylphenidate does not improve interference control during a working memory task in young patients with attention-deficit hyperactivity disorder.
    Prehn-Kristensen A; Krauel K; Hinrichs H; Fischer J; Malecki U; Schuetze H; Wolff S; Jansen O; Duezel E; Baving L
    Brain Res; 2011 May; 1388():56-68. PubMed ID: 21385569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.